Skip to main content

Hypoplasminogenemia

1
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
3 programs
1
PlasminogenPhase 2/31 trial
PlasminogenN/A1 trial
RyplazimN/A1 trial
Active Trials
NCT03265171No Longer Available
NCT03642691No Longer Available
NCT02690714Completed15Est. Oct 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BioTherapeutics IncPlasminogen

Clinical Trials (3)

Total enrollment: 15 patients across 3 trials

A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia

Start: May 2016Est. completion: Oct 201815 patients
Phase 2/3Completed

A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical Trial

N/ANo Longer Available

A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous

N/ANo Longer Available

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.